文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

一项关于两种重组二聚体 RBD COVID-19 疫苗候选物的随机、双盲 I 期临床试验：安全性、反应原性和免疫原性。

A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity.

机构信息

National Centre of Toxicology (CENATOX), 31 Ave. and 114 Street, Marianao, Havana, Cuba.

Finlay Vaccine Institute. 21(st) Ave. N° 19810 between 198 and 200 Streets, Atabey, Playa, Havana, Cuba.

出版信息

Vaccine. 2022 Mar 18;40(13):2068-2075. doi: 10.1016/j.vaccine.2022.02.029. Epub 2022 Feb 8.

DOI:10.1016/j.vaccine.2022.02.029
PMID:35164986
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8823954/
Abstract

BACKGROUND: The Receptor Binding Domain (RBD) of the SARS-CoV-2 spike protein is the target for many COVID-19 vaccines. Here we report results for phase I clinical trial of two COVID-19 vaccine candidates based on recombinant dimeric RBD (d-RBD). METHODS: We performed a randomized, double-blind, phase I clinical trial in the National Centre of Toxicology in Havana. Sixty Cuban volunteers aged 19-59 years were randomized into three groups (20 subjects each): 1) FINLAY-FR-1 (50 µg d-RBD plus outer membrane vesicles from N. meningitidis); 2) FINLAY-FR-1A-50 (50 µg d-RBD, three doses); 3) FINLAY-FR-1A-25 (25 µg d-RDB, three doses). The FINLAY-FR-1 group was randomly divided to receive a third dose of the same vaccine candidate (homologous schedule) or FINLAY-FR-1A-50 (heterologous schedule). The primary outcomes were safety and reactogenicity. The secondary outcome was vaccine immunogenicity. Humoral response at baseline and following each vaccination was evaluated using live-virus neutralization test, anti-RBD IgG ELISA and in-vitro neutralization test of RBD:hACE2 interaction. RESULTS: Most adverse events were of mild intensity (63.5%), solicited (58.8%), and local (61.8%); 69.4% with causal association with vaccination. Serious adverse events were not found. The FINLAY-FR-1 group reported more subjects with adverse events than the other two groups. After the third dose, anti-RBD seroconversion was 100%, 94.4% and 90% for the FINLAY-FR-1, FINLAY-FR-1A-50 and FINLAY-FR-1A-25 respectively. The in-vitro inhibition of RBD:hACE2 interaction increased after the second dose in all formulations. The geometric mean neutralizing titres after the third dose rose significantly in the group vaccinated with FINLAY-FR-1 with respect to the other formulations and the COVID-19 Convalescent Serum Panel. No differences were found between FINLAY-FR-1 homologous or heterologous schedules. CONCLUSIONS: Vaccine candidates were safe and immunogenic, and induced live-virus neutralizing antibodies against SARS-CoV-2. The highest values were obtained when outer membrane vesicles were used as adjuvant. TRIAL REGISTRY: https://rpcec.sld.cu/en/trials/RPCEC00000338-En.

摘要

背景：SARS-CoV-2 刺突蛋白的受体结合域（RBD）是许多 COVID-19 疫苗的靶点。在此，我们报告了两种基于重组二聚体 RBD（d-RBD）的 COVID-19 候选疫苗的 I 期临床试验结果。

方法：我们在哈瓦那国家毒理学中心进行了一项随机、双盲、I 期临床试验。60 名 19-59 岁的古巴志愿者被随机分为三组（每组 20 名）：1）FINLAY-FR-1（50μg d-RBD 加脑膜炎奈瑟菌外膜囊泡）；2）FINLAY-FR-1A-50（50μg d-RBD，三剂）；3）FINLAY-FR-1A-25（25μg d-RBD，三剂）。FINLAY-FR-1 组随机分为接受相同候选疫苗的第三剂（同源方案）或 FINLAY-FR-1A-50（异源方案）。主要结局是安全性和反应原性。次要结局是疫苗免疫原性。使用活病毒中和试验、抗 RBD IgG ELISA 和 RBD：hACE2 相互作用的体外中和试验评估基线和每次接种后的体液反应。

结果：大多数不良事件为轻度（63.5%）、自限性（58.8%）和局部性（61.8%）；69.4%与疫苗接种有因果关系。未发现严重不良事件。与其他两组相比，FINLAY-FR-1 组报告的不良事件更多。第三剂后，FINLAY-FR-1、FINLAY-FR-1A-50 和 FINLAY-FR-1A-25 的抗 RBD 血清转化率分别为 100%、94.4%和 90%。所有配方的第二剂后，RBD：hACE2 相互作用的体外抑制均增加。与其他配方和 COVID-19 恢复期血清组相比，FINLAY-FR-1 组接种第三剂后，活病毒中和抗体滴度显著升高。在 FINLAY-FR-1 同源或异源方案之间未发现差异。

结论：候选疫苗安全且具有免疫原性，可诱导针对 SARS-CoV-2 的活病毒中和抗体。当使用外膜囊泡作为佐剂时，获得了最高值。

试验注册：https://rpcec.sld.cu/en/trials/RPCEC00000338-En。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1cf3/8823954/04fa1bd4e46b/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1cf3/8823954/ae8481a774d4/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1cf3/8823954/04fa1bd4e46b/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1cf3/8823954/ae8481a774d4/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1cf3/8823954/04fa1bd4e46b/gr2_lrg.jpg

相似文献

[1]
A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity.

Vaccine. 2022-3-18

[2]
Safety and immunogenicity of the FINLAY-FR-1A vaccine in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trial.

Lancet Respir Med. 2022-8

[3]
Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials.

Vaccine. 2022-7-29

[4]
Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein vaccine (FINLAY-FR-1A) in children.

Int J Infect Dis. 2023-1

[5]
Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam.

Vaccine. 2022-6-9

[6]
Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.

Lancet Microbe. 2022-3

[7]
Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.

Lancet Infect Dis. 2021-8

[8]
Safety and immunogenicity of COReNAPCIN, a SARS-CoV-2 mRNA vaccine, as a fourth heterologous booster in healthy Iranian adults: A double-blind, randomized, placebo-controlled, phase 1 clinical trial with a six-month follow-up.

Int Immunopharmacol. 2024-6-15

[9]
Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults.

Med. 2022-11-11

[10]
Efficacy and Safety of a Protein-Based SARS-CoV-2 Vaccine: A Randomized Clinical Trial.

JAMA Netw Open. 2023-5-1

引用本文的文献

[1]
Safety and immunogenicity of a SARS-CoV-2 recombinant protein subunit vaccine adjuvanted with Alum + CpG 1018 in healthy Indonesian adults: A multicenter, randomized, comparative, observer-blind, placebo-controlled phase 2 study.

Hum Vaccin Immunother. 2024-12-31

[2]
Comparative assessment of a COVID-19 vaccine after technology transfer to Iran from critical quality attributes to clinical and immunogenicity aspects.

Sci Rep. 2024-11-5

[3]
Bacterial Membrane Vesicles as a Novel Vaccine Platform against SARS-CoV-2.

Curr Microbiol. 2024-8-20

[4]
Immunogenicity and safety of adjuvant-associated COVID-19 vaccines: A systematic review and meta-analysis of randomized controlled trials.

Heliyon. 2023-11-28

[5]
Nanograms of SARS-CoV-2 spike protein delivered by exosomes induce potent neutralization of both delta and omicron variants.

PLoS One. 2023

[6]
CHO-produced RBD-Fc subunit vaccines with alternative adjuvants generate immune responses against SARS-CoV-2.

PLoS One. 2023

[7]
Broad humoral immunity generated in mice by a formulation composed of two antigens from the Delta variant of SARS-CoV-2.

Arch Virol. 2023-6-23

[8]
Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial.

Lancet Reg Health Am. 2023-2

[9]
Efficacy and safety of COVID-19 vaccines.

Cochrane Database Syst Rev. 2022-12-7

[10]
Interim analysis from a phase 2 randomized trial of EuCorVac-19: a recombinant protein SARS-CoV-2 RBD nanoliposome vaccine.

BMC Med. 2022-11-30

本文引用的文献

[1]
Target Product Profile Analysis of COVID-19 Vaccines in Phase III Clinical Trials and Beyond: An Early 2021 Perspective.

Viruses. 2021-3-5

[2]
Self-Reported Real-World Safety and Reactogenicity of COVID-19 Vaccines: A Vaccine Recipient Survey.

Life (Basel). 2021-3-17

[3]
A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine.

Vaccine. 2021-5-12

[4]
Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine.

N Engl J Med. 2021-5-13

[5]
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.

Lancet Infect Dis. 2021-2

[6]
The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development.

Front Immunol. 2020-8-19

[7]
Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies.

Nat Microbiol. 2020-9-9

[8]
Immunological considerations for COVID-19 vaccine strategies.

Nat Rev Immunol. 2020-9-4

[9]
Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine.

N Engl J Med. 2020-9-2

[10]
A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity.

Nature. 2020-7-29

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索